|
Translational Research Programs for Treating Levodopa?induced Dyskinesia| old_uid | 9957 |
|---|
| title | Translational Research Programs for Treating Levodopa?induced Dyskinesia |
|---|
| start_date | 2011/05/12 |
|---|
| schedule | 10h30 |
|---|
| online | no |
|---|
| details | Invité par V. Sgambato-Faure du Centre de Neuroscience Cognitive (UMR5229) |
|---|
| summary | Parkinson’s disease is primarily caused by degeneration of dopaminergic neurons in the substantia nigra and the consequent deficit of dopamine in the striatum. Dopamine replacement therapy with the dopamine precursor L-DOPA is the mainstay of current treatment. However, after several years the patients develop L-DOPA-induced dyskinesia, or abnormal involuntary movements, likely due to excessive signaling via dopamine receptors. In this context, multiple targets and pathways may be amenable to development of gene therapy approaches for Parkinson’s disease. The presentation will highlight comprehensive programs from the speaker’s laboratory that feature target identification, target validation and proof-of-concept preclinical studies in disease-relevant animal model. Such combination constitutes the required preclinical package before embarking into clinical development. While gene therapy has been mostly used so far for enhancing the expression of the target gene, the use of dominant negative or siRNA opens new possibilities. This, combined with the key feature of gene delivery that offer access to intracellular signalling pathways, is likely to further expand the number of proposed targets to be studied. |
|---|
| responsibles | Béranger |
|---|
| |
|